BPC-157 oral (60 × 500 mcg tablets)
Also known as · BPC-157 sublingual tablets
Oral tablet presentation of BPC-157. The Sikirić literature notes stability of BPC-157 in gastric juice; this format enables oral-route research protocols.
Chemistry quick-facts
- CAS
- 137525-51-0
- Formula
- C62H98N16O22
- MW
- 1419.55 Da
- Length
- 15 aa
- Status
- Preclinical only for BPC-157 generally. Oral bioavailability of the peptide is an active area of research; no approved indication.
- Purity (HPLC)
- ≥ 99.4% active
Mechanism of action
Same as the 15 mg injectable presentation.
Research context
The Sikirić group has reported that BPC-157 is stable in human gastric juice over extended periods — a finding frequently cited as support for oral-route research. The 60-tablet supply covers extended in vitro absorption-research protocols.
Oral bioavailability data for BPC-157 is sparse in the published literature. The format is provided for researchers specifically investigating oral-route work.
Published studies
A non-exhaustive list of peer-reviewed studies referenced when curating this entry. Click through to the primary source for the full text.
- Sikirić P, et al. (2013). BPC 157 — gastric juice stability. Current Pharmaceutical Design.
Reconstitution
- Solvent
- N/A — tablets
- Typical volume
- N/A
- · Tablets are sealed in foil blister; store as-received.
Storage
- Lyophilised
- Room temperature, dry, sealed. Avoid direct light.
- Reconstituted
- N/A
- Shelf life — sealed
- 24 months sealed at room temperature.
FAQ
Is oral BPC-157 bioavailable?+
The gastric stability of BPC-157 has been reported. Absorption and systemic bioavailability are active research questions with limited published human data.
This page summarises the research literature on BPC-157 oral (60 × 500 mcg tablets) for in vitro laboratory investigation only. It is not medical advice, not a treatment recommendation, and not a substitute for a qualified physician. Material is sold for analytical chemistry and cell-culture research, not for human or veterinary administration.
- ResearchBPC-157 + TB-500 10/10 mg kit
The most-requested regenerative-peptide kit in the catalogue. BPC-157 and thymosin β-4 combined in a single lyophilised vial — commonly paired in prec
- ResearchBPC-157 15 mg
15-residue synthetic pentadecapeptide. Most extensively studied in rodent tendon, ligament, skin, and gastric-mucosal models.
- ResearchTB-500 10 mg
Synthetic full-length 43-residue thymosin β-4. The most abundant intracellular actin-sequestering peptide in mammalian tissues.
- Biomarkerhs-CRP 2.5 mg/L
High-sensitivity C-reactive protein at 2.5 mg/L sits in the 'intermediate cardiovascular risk' category most cardiology research uses. What it measures, what drives it, and how to interpret your number.
- ComparisonBPC-157 vs TB-500 — research differences and combined-use literature
BPC-157 and TB-500 (thymosin beta-4 fragment) are the two most-studied research peptides in tissue-repair literature. Their mechanisms differ — what the research shows, and why they're often paired in protocol papers.
- ComparisonBPC-157 acetate vs arginate — salt forms compared
BPC-157 is sold as either the acetate or arginate salt. The arginate form has improved stability across pH variations; acetate is the historical default.